Photo by nci from unsplash
tal response in stage IB/IIA demonstrates meaningful clinical benefit with MOGA in early stage MF pts previously treated with systemic therapies despite MAVORIC not being powered to determine treatment effect… Click to show full abstract
tal response in stage IB/IIA demonstrates meaningful clinical benefit with MOGA in early stage MF pts previously treated with systemic therapies despite MAVORIC not being powered to determine treatment effect by disease stage. Sponsor: Kyowa Kirin.
Keywords:
phase evaluation;
response;
trial phase;
stage;
ncri petrea;
petrea trial
Journal Title: Hematological Oncology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Hematological Oncology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!